SP3 and neoplasm: Moreover, several studies report that high expression of Sp1 and, in some cases, Sp3 in tumor vs. non-tumor tissue are negative prognostic factors for patients with pancreatic, glioma, colon, gastric, head and neck, prostate, lung and breast cancers [5–13].